Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Details 2)

v3.19.3
Stockholders' Equity (Details 2)
9 Months Ended
Sep. 30, 2019
$ / shares
shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Total Outstanding | shares 7,656,396
Stock Options, Number Exercisable | shares 4,646,317
Grant Price From 0.26 To 2.02 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 0.26
Stock Options, Grant Price, Maximum 2.02
Stock Options, Weighted Average Exercise Price $ 0.89
Stock Options, Total Outstanding | shares 3,298,353
Stock Options, Number Exercisable | shares 3,282,936
Stock Options, Weighted Average Remaining Contractual Term 3 years 8 months 9 days
Grant Price From 2.10 To 4.60 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 2.10
Stock Options, Grant Price, Maximum 4.60
Stock Options, Weighted Average Exercise Price $ 2.47
Stock Options, Total Outstanding | shares 3,665,043
Stock Options, Number Exercisable | shares 936,167
Stock Options, Weighted Average Remaining Contractual Term 8 years 10 months 21 days
Grant Price From 5.30 To 8.86 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 5.30
Stock Options, Grant Price, Maximum 8.86
Stock Options, Weighted Average Exercise Price $ 6.62
Stock Options, Total Outstanding | shares 693,000
Stock Options, Number Exercisable | shares 427,214
Stock Options, Weighted Average Remaining Contractual Term 8 years 7 months 10 days